Cargando…

Esketamine vs Midazolam in Boosting the Efficacy of Oral Antidepressants for Major Depressive Disorder: A Pilot Randomized Clinical Trial

IMPORTANCE: Loss of a previously effective response while still using adequate antidepressant treatment occurs in a relatively high proportion of patients with major depressive disorder (MDD); therefore, there is a need to develop novel effective treatment strategies. OBJECTIVE: To assess the effica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiao, Chunfeng, Zhou, Jia, Li, Anning, Zhang, Ling, Zhu, Xuequan, Zhou, Jingjing, Hu, Yongdong, Zheng, Yunying, Liu, Jing, Deng, Qiying, Wang, Haibo, Wang, Gang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2023
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425830/ https://www.ncbi.nlm.nih.gov/pubmed/37578792 http://dx.doi.org/10.1001/jamanetworkopen.2023.28817

Ejemplares similares

Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium
por: Vázquez, Gustavo H., et al.
Publicado: (2021)

Is (S)-norketamine an alternative antidepressant for esketamine?
por: Hashimoto, Kenji, et al.
Publicado: (2018)

Venlafaxine vs. fluoxetine in postmenopausal women with major depressive disorder: an 8-week, randomized, single-blind, active-controlled study
por: Zhou, Jingjing, et al.
Publicado: (2021)

Electroconvulsive therapy vs Esketamine among patients with Major Depressive Episode
por: Basto, M. D. R. D. R. F. D. A., et al.
Publicado: (2023)

Urothelial toxicity of esketamine in the treatment of depression
por: Findeis, Hannelore, et al.
Publicado: (2020)

Midazolam Attenuates Esketamine-Induced Overactive Behaviors in Mice Before the Sedation, but Not During the Recovery
por: Chu, Qinjun, et al.
Publicado: (2022)

The antidepressant effect and safety of non-intranasal esketamine: A systematic review
por: Smith-Apeldoorn, Sanne Y, et al.
Publicado: (2022)

Adverse Effects of Esketamine for the Treatment of Major Depression Disorder: Findings from Randomized Controlled Trials
por: Yang, Siyuan, et al.
Publicado: (2021)

Efficacy and Safety of Esketamine for Supplemental Analgesia During Elective Cesarean Delivery: A Randomized Clinical Trial
por: Xu, Li-Li, et al.
Publicado: (2023)

Intranasal esketamine combined with oral midazolam provides adequate sedation for outpatient pediatric dental procedures: a prospective cohort study
por: Wang, Jing, et al.
Publicado: (2023)

Efficacy and Safety of Esketamine Combined with Antidepressants for Treatment-Resistant Depression: A Meta-Analysis
por: Liu, Peng, et al.
Publicado: (2022)

Effect of Intraoperative Esketamine Infusion on Postoperative Sleep Disturbance After Gynecological Laparoscopy: A Randomized Clinical Trial
por: Qiu, Di, et al.
Publicado: (2022)

Effect of esketamine on perioperative depressive symptoms in major surgery patients (PASSION II): study protocol for a randomised controlled trial
por: Zhou, Yang, et al.
Publicado: (2022)

Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants
por: Rotroff, D M, et al.
Publicado: (2016)

Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression
por: Chen, Guang, et al.
Publicado: (2022)

The use of esketamine in the treatment of patients with oral antidepressant-resistant depression: systematic review and meta-analysis
por: Floriano, Idevaldo, et al.
Publicado: (2023)

Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorder
por: Wen, X.J., et al.
Publicado: (2014)

Antidepressants normalize elevated Toll-like receptor profile in major depressive disorder
por: Hung, Yi-Yung, et al.
Publicado: (2015)

Comparison between oral midazolam versus oral ketamine plus midazolam as preanesthetic medication in autism spectrum disorder: double-blind randomized clinical trial
por: Penna, Heber de Moraes, et al.
Publicado: (2022)

Effect of intravenous midazolam on cardiac parameters in acute tricyclic antidepressants poisoning
por: Eizadi-Mood, Nastaran, et al.
Publicado: (2016)

Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study
por: Morrison, Randall L., et al.
Publicado: (2018)

Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study
por: Breeksema, Joost J., et al.
Publicado: (2023)

Development and Internal Validation of a Novel Model to Identify Inflammatory Biomarkers of a Response to Escitalopram in Patients With Major Depressive Disorder
por: Zhou, Jingjing, et al.
Publicado: (2021)

Comparison of Midazolam and Propofol for BIS-Guided Sedation During Regional Anaesthesia
por: Khurana, Priyanka, et al.
Publicado: (2009)

Scopolamine augmentation of a newly initiated escitalopram treatment for major depressive disorder: study protocol for a randomized controlled trial
por: Zhou, Jingjing, et al.
Publicado: (2019)

Tissue-Specific Oxysterols as Predictors of Antidepressant (Escitalopram) Treatment Response in Patients With Major Depressive Disorder
por: Sun, Zuoli, et al.
Publicado: (2023)

Case report: Intranasal esketamine for severe major depressive disorder with psychotic features
por: Carter, Maximilian, et al.
Publicado: (2022)

Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality
por: Fu, Dong-Jing, et al.
Publicado: (2023)

Benefit–Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment‐Resistant Depression
por: Katz, Eva G., et al.
Publicado: (2020)

Effectiveness of Genotype-Specific Tricyclic Antidepressant Dosing in Patients With Major Depressive Disorder: A Randomized Clinical Trial
por: Vos, Cornelis F., et al.
Publicado: (2023)

Serum amyloid A levels in acute and chronic urticaria
por: Lu, Wei, et al.
Publicado: (2019)

Pitfalls of Cost-Effectiveness Analysis in Practice: A TRD Case Example in the United States with Esketamine Versus Oral Antidepressants
por: Karkare, Swapna, et al.
Publicado: (2020)

The effects of intramuscular administration of scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled trial
por: Zhou, Jingjing, et al.
Publicado: (2020)

The effects of intranasal esketamine (84 mg) and oral mirtazapine (30 mg) on on-road driving performance: a double-blind, placebo-controlled study
por: van de Loo, Aurora J. A. E., et al.
Publicado: (2017)

Multi-omics reveal microbial determinants impacting the treatment outcome of antidepressants in major depressive disorder
por: Wang, Yaping, et al.
Publicado: (2023)

The efficacy and safety of esketamine in the treatment of major depressive disorder with suicidal ideation: study protocol for a randomized controlled trial
por: Liu, Haiyan, et al.
Publicado: (2022)

Esketamine Anesthetizes Mice With a Similar Potency to Racemic Ketamine
por: Ma, Xiaofan, et al.
Publicado: (2023)

Effect of Rivaroxaban vs Enoxaparin on Major Cardiac Adverse Events and Bleeding Risk in the Acute Phase of Acute Coronary Syndrome: The H-REPLACE Randomized Equivalence and Noninferiority Trial
por: Zhou, Shenghua, et al.
Publicado: (2023)

Low-dose midazolam for anxiolysis for pregnant women undergoing cesarean delivery: a randomized trial
por: Oliveira, Pedro Solfa Campos, et al.
Publicado: (2021)

Group-Based Symptom Trajectory of Intramuscular Administration of Scopolamine Augmentation in Moderate to Severe Major Depressive Disorder: A Post-Hoc Analysis
por: Wang, Xiao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mer21vk1mglnp9d3j0ltncdv5t